Please read up on the company before making non-informative statements.
Lets start off with some independent analysis - RBS Morgans Report - 25th August 2010
"What is the potential?
In the US, Arixtra recorded US$251m in sales in FY10 for GSK (+30% on the pcp). ACL
earns a 50-60% share of profits from Dr Reddy?s, equating to a 30-35% effective royalty rate.
We estimate ACL will receive A$32.0m, A$32.0m, A$47.1m and A$45.2m over FY12-15."
Whilst I encourage scruitiny as a shareholder of ACL, I take it upon myself and regularly talk to PS and other investors/analysts to ensure my investment is sound and ask questions direct to the key people to ensure that we are not getting taken for a ride. I suggest that you give Alchemia a call if you have something on your chest and speak with PS.
- Forums
- ASX - By Stock
- long wait
Please read up on the company before making non-informative...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable